India: Patent On Traditional Knowledge- Patent Office Decision On Development Center For Biotechnology (Taiwan) Vs CSIR

Last Updated: 26 January 2015
Article by Saipriya Balasubramanian

Most Read Contributor in India, September 2016

In a recent decision taken against the pre-grant opposition filed by the Council of Scientific & Industrial Research, the Patent Office granted patent rights for the invention titled "A Pharmaceutical Composition And Process Thereof For The Preparation Of Plant Extracts For Treating Skin Disorders And Enhancing Healing Of Wounds" (provisionally numbered as 1556/ KOL/2007)" filed by Development Center For Biotechnology (The Applicant), a Taiwanese company. The grounds of Opposition are lack of novelty and inventive step. A detailed analysis of the case is as follows,

The Applicant has amended the claims twice one before filing the Pre-grant opposition followed by the final amended set of claims after filing the Pre-grant opposition. The claims are processing, extraction, composition and use claims. The first 10 claims in 'as filed' format comprise of a process for the preparation of Plectanthus amboinicus extracts, a plant extract. The said process is being prepared by a stirring separation method. Further Claims 4 to 10 comprise of the step involved in stirring separation method of the extract. Claim 11 to 16 comprises of the pharmaceutical composition and amount of Centella asiatica Urban extract. Claims 17 to 20 comprise of the use of the Pharmaceutical composition extracted from Plectanthus amboinicus.

In the amended claims, claims 14, 15 and 16 were deleted by the applicant during prosecution as they were 'use' claims. Claims 11 to 16 where objected to by the opponent (CSIR).

The Opponent has quoted " the following claims are included in the third party observation." However, no arguments have been made against the remaining claims.

Claims 11 to 16 that are disputed read as follows:

"11. The pharmaceutical composition as claimed in claim 10 further comprising a therapeutically effective amount of Centella asiatica Urban extract.

12. The pharmaceutical composition as claimed in claim 11, wherein the Plectranthus amboinicus extract and the Centenella asiatica Urban extract have a weight ratio of about 1:60 to about 1:4.

13. A wound dressing comprising a pharmaceutical composition as claimed in any one of claims 10 to 12.

14. A use of the pharmaceutical composition of any one of claims 10 to 12 in the manufacture of a medicament for treating skin disorder.

15. The use as claimed in claim 14 wherein the disorder is general trauma or bedsores.

16. The use as claimed in claim 14 wherein the skin disorder is wounds in a diabetic patient."

The Opponent has filed a Pre-grant Opposition by way of representation on 19/06/2012. The Patent Office acknowledged the role of CSIR as the general opponent in the field of Traditional Knowledge based patent applications. Further, CSIR is found to file documents prepared by them under the programme of the preparation of Traditional Knowledge Digital Library ( TKDL) to prevent the persons to claim patent right over the traditional knowledge.

CSIR-TKDL practice

It was further stated that as per practice CSIR-TKDL always submitted prior-art evidences available in TKDL with respect to patent applications filed on India's Traditional knowledge at International Patent Office's but has never been a part of hearing process in patent offices. Hence there was no personal representative in any of the Pre-grant Opposition hearings. Therefore in the present case, the hearing proceeded in the presence of the applicant representative only.

The opponent had annexed 11 documents at the time of filing Pre-grant opposition in languages other than English for which the translations in English have been filed. The cited documents mainly referred to Centella asiatica and no reference was made to Plectranthus amboinicus in terms of its method of preparation, extraction, and composition as well its use in wound healing.

The Applicant's arguments:

The Applicant had primarily argued that the opponent has merely provided documents from TKDL without providing verified translation. The agent of the applicant challenged the validity of the translations by making reference to Patent Rule 61(2) that requires production of verified translations. However, the applicant did not attempt to prove that the translations are wrong. On the question of authorised translator, the Controller held that CSIR is funded by the Government and as stated by them in their annex has an agreement with Patent office to share the TKDL for the purpose of search during prosecution of the filed patent applications and disposing them on merits. Therefore translations filed by CSIR are deemed authenticated by the Government itself. Therefore the translations were considered for the disposal of the present case.

The Controller further stated that the present opposition filed by the opponent is loosely drafted and do not even set out the grounds of opposition. Further, the Controller pointed that in a contested opposition preceding the grounds ought to be pleaded and proved. In absence of pleadings such proceeding ought to be outright rejected.

As seen from above claims 11-16 are disputed. Claims 14,15 and 16 were deleted during prosecution as the said claims are 'use' claims and do not fall within the scope of Section 2(1)(j) of the Patents Act.

Claims 11 to 13:

Defending Claims 11 to 13, the Applicant stated that Claim 11 is dependant claim on the previous claim. It is noteworthy to state that claims 1 to 10 of the present invention are not opposed. Further, the annexed documents refer to Centella asiatica Urban throughout which is an optional feature of the present invention. It is admitted that though the extract of Plectranthus amboinicus is known, the existing techniques of extractions (e.g. column chromatography) are cumbersome, time consuming and do not produce large quantities. The present invention, through the stirring separation technique, provides better and faster extraction. Also better wound healing efficacy is observed in P.amboinicus and Centella asiatica combination.

Therefore, it was prayed by the Applicant that the Claims 11 to 13 are novel and inventive and hence be allowed.

Analysis and Decision of the Controller

The Controller assessed the novelty of the present invention based on the latest filed claims as well as the documents provided by the Opponent and observed that while filing opposition it is not correct to conclude that the opponent is not aware about the first 10 claims of the present specification. In the absence of any documental evidence about the extract of Plectanthus amboiinicus prepared by stirring method and its use for wound healing novelty of the first 10 claims has been upheld by the Controller.

The combination of Plectanthus amboiinicus and Centella asiatica as claimed in claim 11 is not mentioned by the opponent as either published prior to the priority date or prior claimed or been in the public domain before the priority date of the present application. Therefore, Claim 11 is considered Novel. Claim 12 is dependent on Claim 11 which defines the specific ration of the two constituents also considered as novel.

Claim 13 defines an independent claim, claiming a product that is a "wound dressing" which in turn comprises either the extract of Plectanthus amboinicus or the combined extracts of Plectranthus amboinicus and Centella asiatica. Hence Claim 13 is also novel.

The Applicant has acknowledged about the existence of the extract of Plectranthus amboinicus from US patent applications 2006/0099283 A1 and USSN 11/605,178. The extraction in the said patent documents was carried out by column chromatography. However the drawbacks of traditional column chromatography methods are cumbersome, timeconsuming, large quantity of the active ingredient is unavailable. Hence the present process that is stirring separation is superior to column chromatography or centrifugal separation because Example 1 of the specification explains that yield of the active is shown as 0.94% whereas Example 2 of the specification explains the preparation of Plectranthus amboinicus extracts by column chromatography separation method that is the process of the prior art wherein the yield of the active is shown as 0.67%. Therefore, there exists the technical advancement as compared to the existing knowledge hence satisfying the requirement of the Section 2(1)(ja) of the Patents Act, thus the "inventive step" is established.


Though the opponent had pointed the lack of novelty and inventive step, but could not prove it. The opponent's main objection is for Centella asiatica which is only an option in the present invention. The Opponent had made no references to the extract of Plectranthus amboinicus nor to its method neither of preparation nor to a combination nor to its use for skin disorders. Based on the aforesaid, it has been decided to grant the patent right to the applicant.



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.